{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:27:33Z","timestamp":1784129253617,"version":"3.55.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Heart failure (HF) affects approximately 6 million Americans and is projected to increase in prevalence as the population ages. While progress has been made in the treatment of heart failure with reduced ejection fraction (HFrEF), treatments for heart failure with preserved ejection fraction (HFpEF) are few and far between. Since HFpEF makes up half of all heart failure cases, its management may be the biggest unmet need in cardiology. Results from the recent EMPEROR-Preserved trial are encouraging. After 26 months, patients with HFpEF who used the sodium-glucose co-transporter 2 inhibitor empagliflozin had a lower risk of hospitalization for HF than patients taking a placebo. However, the trial did not show empagliflozin to reduce the risk of cardiovascular death, unlike the EMPEROR-Reduced trial, in which empagliflozin was associated with a reduced risk of both cardiac death and hospitalization for patients with HFrEF. The outcomes of these trials highlight the dissimilarities between the two diseases. While HFrEF is mainly a disease of cardiomyocyte injury and systolic dysfunction, HFpEF is a multifactorial syndrome of inflammation and endothelial dysfunction stemming from chronic diseases like hypertension, diabetes and obesity. While trials of empagliflozin for HFpEF did not show a mortality benefit, sodium-glucose co-transporter 2 inhibitors are promising additions to the management of HFpEF for their effects on the disease\u2019s risk factors through weight loss, natriuresis, blood pressure lowering, and glycemic control.<\/jats:p>","DOI":"10.1097\/crd.0000000000000501","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:36:05Z","timestamp":1675355765000},"page":"263-266","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications"],"prefix":"10.1097","volume":"32","author":[{"given":"Aaron","family":"Plosker","sequence":"first","affiliation":[{"name":"Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WIlliam H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College\/Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update. a report from the American Heart Association.","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cpcardiol.2015.12.002","article-title":"Heart failure with preserved ejection fraction.","volume":"41","author":"Reddy","year":"2016","journal-title":"Curr Probl Cardiol"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding.","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial.","volume":"145","author":"Butler","year":"2021","journal-title":"Circulation"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMe2113008","article-title":"SGLT2 inhibition in heart failure with a preserved ejection fraction \u2013 a win against a formidable foe.","volume":"385","author":"Drazner","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"L77","DOI":"10.1093\/eurheartj\/suaa140","article-title":"The PARAGON-HF trial: the sacubitril\/valsartan in heart failure with preserved ejection fraction.","volume":"22","author":"Gronda","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Heart failure clinical research network investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvaa217","article-title":"Metabolic inflammation in heart failure with preserved ejection fraction.","volume":"117","author":"Schiattarella","year":"2021","journal-title":"Cardiovasc Res"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/CIRCRESAHA.116.310119","article-title":"Why don\u2019t we have proven treatments for HFpEF?","volume":"120","author":"Roh","year":"2017","journal-title":"Circ Res"},{"key":"R18-20250619"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction.","volume":"75","author":"Kjeldsens","year":"2020","journal-title":"Hypertension"},{"key":"R20-20250619","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guidelines for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:02:57Z","timestamp":1750348977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000501","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}